ludo king hack app PARP inhibitor olaparib achieves primary endpoint in phase 3 clinical trial for prostate cancer Vertex's cystic fibrosis combination therapy receives priority review and is expected ...

INR:6644. ipl toss betting app A number of designated medical institutions and medical insurance pharmacies were withdrawn from GSP and their service agreeme ...

INR:2392. san siro horse racing venue New leukemia drug! Astellas' Xospata is recommended for approval by the EU CHMP New drug for cystic fibrosis! EC ...

The top 10 pharmaceutical stocks are released! Hengrui Medicine aims to hit a market value of 370 billion yuan ASH | BTK inhibitor development trends: Eli Lilly, BeiGene, and AZ announce clinical resu ...

INR:7515. online legal betting Selected by Science's annual breakthrough list: Is a cure for cystic fibrosis just around the corner? Many provinces have intr ...

According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

Krystal Biotech's VYJUVEK, a groundbreaking gene therapy for DEB, achieved $83.8M in Q3 2024 sales. Read why I rate KRYS ...

In STAT's "jealousy list" for 2024, STAT staffers explain what makes a selection of stories they read in other publications ...

A $42,000 grant from NASA and INBRE will further CF research, through a collaborative effort spanning to India and the United Kingdom.

The Food and Drug Administration (FDA) has approved Alyftrek ™ (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one ...

Jurrien Timmer, Director of Global Macro at Fidelity Management & Research Company, recently shared his outlook for the stock ...

Changing Futures, a nonprofit dedicated to advancing cystic fibrosis (CF) research, will hold a polar plunge at noon New Year ...